Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) EVP David Altshuler sold 3,231 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the sale, the executive vice president now owns 26,512 shares of the company’s stock, valued at approximately $13,256,000. This trade represents a 10.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Vertex Pharmaceuticals Price Performance
Shares of NASDAQ:VRTX opened at $504.77 on Friday. The business has a 50 day moving average price of $457.74 and a 200 day moving average price of $462.02. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The company has a market cap of $129.62 billion, a price-to-earnings ratio of -229.44, a PEG ratio of 2.11 and a beta of 0.41. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.
Hedge Funds Weigh In On Vertex Pharmaceuticals
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on VRTX. Cantor Fitzgerald restated an “overweight” rating and issued a $480.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Scotiabank boosted their target price on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 11th. Barclays boosted their target price on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 11th. StockNews.com raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Piper Sandler cut their target price on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Ten analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $506.70.
Read Our Latest Stock Analysis on Vertex Pharmaceuticals
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- How to Use Stock Screeners to Find Stocks
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- 5 Top Rated Dividend Stocks to Consider
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- What Investors Need to Know About Upcoming IPOs
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.